Abstract

A retrospective study of 176 treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) that had undergone intravitreal aflibercept treatment (2.0 mg, 7–8 times over one year) was performed to correlate the effect of aflibercept on the morphological features of nAMD—subretinal hyper-reflective material (SHRM), pigment epithelial detachment (PED), subretinal fluid (SRF), and intraretinal fluid (IRF)—with visual acuity at baseline and at one year. Spectral-Domain Optical Coherence Tomography (SD-OCT) images and best-corrected visual acuity (BCVA) at baseline and at one year were obtained. The relationship between visual acuity and the presence of morphological features at baseline and at one year was statistically analysed. The proportion of eyes with PED (p = 0.01), SRF (p ≤ 0.001), and IRF (p ≤ 0.001) reduced at one year. SHRM (p = 0.002) and IRF (p = 0.0001) were associated with poorer baseline BCVA. The presence of SRF at baseline was associated with better baseline BCVA (p = 0.004) and 5.3 letters of improvement of BCVA after one year of treatment (p = 0.0001). For each letter increase in BCVA at baseline, 0.25 fewer letters were gained in BCVA at one year. While aflibercept can improve morphological abnormalities in nAMD, this is not always accompanied by a corresponding improvement in visual acuity.

Highlights

  • The management of neovascular age-related macular degeneration was revolutionised by the introduction of intravitreal vascular endothelial growth factor (VEGF) inhibition [1]

  • A retrospective analysis was performed to investigate the change in visual acuity and foveal morphology in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) after one year of intravitreal aflibercept treatment

  • We found that after one year of the recommended regimen of intravitreal aflibercept injections [8,21], a resolution or a decrease in size of both subretinal fluid (SRF) and intraretinal fluid (IRF) was observed in most treated eyes

Read more

Summary

Introduction

The management of neovascular age-related macular degeneration (nAMD) was revolutionised by the introduction of intravitreal vascular endothelial growth factor (VEGF) inhibition [1]. The use of anti-VEGF agents has lead to major improvements in treatment and prognosis in nAMD [2]. Recurrent neurosensory disturbance with ensuing damage as seen in untreated nAMD invariably leads to irreversible loss of vision [6], and an improved understanding of factors that affect the interaction between treatments and nAMD progression may help to address these concerns and improve predictability of visual outcomes Morphological features such as intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) have been proposed as potential biomarkers for monitoring the effect

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call